Bengaluru-based precision oncology startup 4baseCare has raised ₹90 crore in the first close of its Series B funding round, marking a strong vote of confidence in the company’s vision to transform cancer care using genomics and artificial intelligence. The round was co-led by seasoned Indian investors Ashish Kacholia and Lashit Sanghvi, with continued participation from existing investor Yali Capital.
The funding comes at a time when demand for personalised cancer treatment is rising rapidly in India and other emerging markets. With this capital, 4baseCare aims to deepen its presence in India while accelerating expansion into global markets where access to advanced cancer diagnostics remains limited.
Founded in 2018 by Hitesh Goswami and Kshitij Rishi, 4baseCare focuses on building population-relevant clinico-genomic datasets that combine genetic and clinical data. This approach helps address a critical gap in oncology, as most global genomic data is skewed towards Western populations, often limiting treatment accuracy for patients in Asia and other regions.
Capital to Support Market Expansion and Hospital Integration
The newly raised funds will be primarily used to expand 4baseCare’s hospital-linked genomics testing infrastructure across India and internationally. The company plans to grow its footprint in the Middle East, Southeast Asia, Latin America, and Central Asia, regions where precision oncology is still in its early stages but seeing increasing adoption.
4baseCare works closely with hospitals and clinicians by embedding its genomics and data solutions directly into cancer care workflows. This enables oncologists to access advanced diagnostic insights alongside routine clinical information, helping them make more informed treatment decisions for patients.
The startup’s strategy focuses on long-term hospital partnerships rather than standalone testing, positioning itself as a trusted clinical intelligence partner rather than just a diagnostics provider.
Scaling AI-Driven Oncology Platform OncoTwin
A key pillar of 4baseCare’s offering is its AI-powered platform, OncoTwin Insights. The platform is designed to assist oncologists by analysing complex genomic and clinical data sets and converting them into actionable treatment recommendations.
OncoTwin Insights supports precision medicine by helping clinicians identify targeted therapies, clinical trial opportunities, and personalised treatment pathways based on a patient’s unique genetic profile. The platform has already gained international recognition for its innovation, strengthening the startup’s credibility in global oncology circles.
With fresh funding in hand, the company plans to further enhance the platform’s AI capabilities, improve turnaround times, and expand clinical use cases across multiple cancer types.
Strong Investor Backing Signals Confidence
The participation of well-known investors Ashish Kacholia and Lashit Sanghvi signals strong confidence in 4baseCare’s business model, technology, and long-term potential. Existing investor Yali Capital doubling down on the startup further reflects belief in its execution and impact in the precision healthcare space.
According to the company, the backing will also help attract top talent, accelerate product innovation, and strengthen collaborations with healthcare institutions and research organisations globally.
Shaping the Future of Precision Oncology
4baseCare’s latest funding round highlights the growing investor interest in healthtech startups that combine AI, genomics, and clinical intelligence. As cancer continues to be a major public health challenge in India, solutions that enable early detection, accurate diagnosis, and personalised treatment are becoming increasingly important.
By focusing on population-specific data and scalable hospital partnerships, 4baseCare is positioning itself as a key player in the next phase of oncology care. With this fresh capital, the startup aims to make precision cancer treatment more accessible, affordable, and effective across India and other emerging markets.